The authors confirmed that regulating the lncRNA-hPVT1/NOP2 pathway may be a therapeutic target in treating HCC given that lncRNA-hPVT1 was shown to promote cell proliferation, cell cycling, and stem cell-like properties in HCC cells by stabilizing the NOP2 protein [32]. This evidence concerns the gene NOP2 and hepatocellular carcinoma.